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Abstract 
Introduction: Maternal vaccination is increasingly part of antenatal care in the UK and 
worldwide. Trials of Group B streptococcus (GBS) vaccines are ongoing. This study 
investigated the attitudes of pregnant women and healthcare professionals towards antenatal 
vaccination, both in routine care and a clinical trial setting. Material and methods: Survey of 269 
pregnant women, 273 midwives/obstetricians and 97 neonatal doctors across seven sites in the 
UK assessing attitudes towards antenatal vaccinations, knowledge of GBS, a hypothetical GBS 
vaccine and participation in clinical vaccine trials. Results: Sixty-eight percent of pregnant 
women intended to receive a vaccine during their current pregnancy (183/269) and 43% (of all 
respondents, 115/269) reported they would be very/fairly likely to accept a vaccine against GBS 
despite only 29% (55/269) knowing what GBS was. This increased to 69% after additional 
information about GBS was provided. Twenty-four percent of pregnant women reported they 
would be likely to take part in a clinical trial of an unlicensed GBS vaccine. Fifty-nine percent of 
maternity professionals and 74% of neonatologists would be likely to recommend participation 
in a GBS vaccine trial to women, with the vast majority (>99%) willing to be involved in such a 
study. Incentives to take part cited by pregnant women included extra antenatal scans and the 
opportunity to be tested for GBS. Conclusion: Pregnant women and healthcare professionals 
were open to the idea of an antenatal GBS vaccine and involvement in clinical trials of such a 
vaccine. Education and support from midwives would be key to successful implementation. 
 
Keywords 
Group B streptococcus, antenatal vaccine, pregnancy, attitudes, healthcare professionals, 
pregnant women, clinical trials 
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Key Message 
Both pregnant women and healthcare professionals were open to the idea of an antenatal Group 
B streptococcus vaccine and involvement in clinical trials of such a vaccine. Education and 
support from midwives would be key to successful implementation. 
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Introduction 
 
Immunisation of pregnant women to protect both themselves and/or their infants is increasingly 
part of routine care both in the UK and worldwide. Current UK recommendations state that all 
pregnant women should receive a pertussis-containing vaccine from 16 to 32 weeks gestation 
and the influenza vaccine during the influenza season, at any stage of gestation (1, 2). There is 
evidence that these antenatal vaccines are both safe, and effective at preventing disease both in 
the mother and the infant (3-7).  
Around 60-75% of UK pregnant women received the pertussis vaccine in 2016 (8), with a 
marked increase between winter 2015 and 2016 (8). However, uptake rates for influenza remain 
sub-optimal with recent figures showing that only 43% of eligible pregnant women received the 
influenza vaccine in 2016 (9); thus a significant proportion of pregnant women and their babies 
remain susceptible to potentially fatal, yet preventable, diseases. 
Antenatal immunisation also offers the potential to target additional major neonatal pathogens 
including Group B streptococcus (GBS), the leading cause of sepsis and meningitis in infants 
under the age of 3 months (10, 11). There was around 850 cases (0.95/1000 live births) of 
culture-proven confirmed GBS cases in the UK and Republic of Ireland in the 13 months from 
April 2014 resulting in 53 deaths (personal communication, unpublished data C. O’Sullivan), 
substantially more than the 14 deaths from neonatal pertussis infections in the 2012 pertussis 
outbreak that prompted the current maternal immunisation strategy (12). Strategies for the 
prevention of neonatal GBS infection include the risk-based intrapartum antibiotic approach 
currently used in the UK (13), or a universal swab-based screening programme used in the USA, 
Canada, much of Europe and parts of Australia (14, 15). Neither strategy impacts on GBS 
disease beyond the first week of life, and both have the potential to miss cases or contribute to 
the overuse of antibiotics. An antenatal vaccine against GBS is therefore desirable and clinical 
trials of candidate GBS vaccines involving over 500 pregnant women have been conducted (16) 
or are ongoing (17).  
The aim of this study was to investigate the attitudes of pregnant women and the healthcare 
professionals involved in their care, towards antenatal vaccination, GBS disease and the prospect 
of a GBS vaccine. Secondary aims included identifying factors affecting vaccine uptake and 
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exploring attitudes towards participating in clinical trials of an antenatal GBS vaccine, and how 
these could be addressed to optimise uptake in a routine setting and in recruitment for clinical 
trials.  
 
Material and methods 
Self-completed paper questionnaires in English were distributed to 356 pregnant women, 407 
maternity professionals (defined as practising midwives or doctors working in obstetric practice) 
and 118 neonatal doctors across seven NHS trusts in the UK. The sites were Oxford University 
Hospitals NHS Foundation Trust, NHS Lothian in Edinburgh, Imperial College Healthcare NHS 
Trust and St George’s University Hospitals NHS Foundation Trust in London, University 
Hospital Southampton NHS Foundation Trust, University Hospitals Bristol NHS Foundation 
Trust and Central Manchester University Hospitals and NHS Foundation Trust. Pregnant women 
were recruited from October 2014 until June 2015, and healthcare professionals from October 
2014 until July 2015.  
Three different questionnaires were developed for each of the groups of interest (Supporting 
Information Appendix S1). Inclusion criteria were that the respondent should be over 18, be able 
to read and write English and be either pregnant or working as a midwife (including community 
midwives), obstetric doctor or neonatal doctor at one of the study sites.  
The questionnaires were developed after reviewing the literature, using data collected from an 
online survey of over one thousand women of child bearing age (18), and in-depth qualitative 
work with pregnant women, parents with experience of GBS and maternity professionals (19). 
Prior to the national survey, the questionnaires were piloted amongst the interview and focus 
group participants and adapted based on their feedback.  
Questionnaires were distributed by study staff in antenatal clinic waiting rooms, antenatal 
classes, multi-professional meetings, staff rooms and via email. Participation was voluntary, the 
questionnaires were confidential, anonymous and no personal identifying information was 
collected. Respondents were asked to tick a box at the beginning of the questionnaire to indicate 
that they understood their answers would be used as part of a research study. Respondents were 
also given a sealed envelope with the GBS additional information sheet (Supporting Information 
Appendix S2) which they were instructed to open at a specified point. 
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Statistical analyses 
Questionnaires were returned to a single site (Oxford) and data entered into the OpenClinca 
database before being exported to the Microsoft Excel software program for analysis. Statistical 
analyses were conducted with Graphpad Prism software (GraphPad, La Jolla, USA)  using Chi-
square and Fisher’s exact tests. Not all questions were fully completed by every respondent, 
however, unless otherwise stated, the percentages stated are of all responses with those who did 
not complete the question recorded as missing data. For the ranking questions, data were 
included even if the respondents only ranked some of the options. However if the respondent 
only ticked, rather than numbered, boxes, this were recorded as “uninterpretable” and counted as 
missing data. 
Ethical approval 
The study was approved by the NRES Committee South Central- Hampshire A ethics committee 
reference 13/SC/0619. The study was funded by a grant from the charity Meningitis Now.  
 
Results  
A total of 356 pregnant women, 407 maternity professionals and 118 neonatal doctors were 
approached to take part in the study and 300 (84.3%), 306 (75.2%) and 101 (85.6%) completed 
the questionnaire, respectively. Of these, 31 pregnant women, 33 maternity professionals and 4 
neonatal doctors were excluded from the final analysis as they had not ticked the ‘permission’ 
box, leaving 269 pregnant women, 273 maternity professionals and 97 neonatal doctors.  
The age of the pregnant women ranged from eighteen to forty-six years and ethnicity was well 
matched for the UK population (20). Further demographic details for all groups are shown in 
Tables 1 and 2.  
Seventy-seven percent (208/269) of the pregnant women recollected being offered at least one 
vaccination during their current pregnancy (Table 1) and 68% (of all respondents, 182/269) 
indicated that they had received or intended to receive a vaccination during this pregnancy, 
19.7% (53/269) did not intend to have any vaccinations and 11.2% (30/269) were undecided. 
Vaccination details for the healthcare professionals are shown in Table 1. When pregnant 
women were asked to rank the relative importance of the potential benefits of antenatal 
vaccination, the highest ranking was protecting their baby from a rare but serious condition, 
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while protecting self or others was less important (figure 1). Major concerns about receiving 
antenatal vaccination were that it might cause harm to the baby and specifically that it may cause 
a miscarriage (figure 2). Factors influencing whether the maternity professionals would 
recommend a vaccine in pregnancy also highlighted the perceived importance of preventing 
serious conditions as 24.2% (66) ranked this as the most important consideration. The existence 
of a national recommendation was also key with 32.2% (88) of maternity professionals stating 
this was the factor which would be most influential.   
Pregnant women reported receiving information about antenatal immunisation from their 
midwife, obstetrician or general practitioner (187, 69.5%), via leaflets (132, 49.1%) or their own 
independent research (46, 17%, multiple answers permitted). However, 18% (49) reported they 
had received no information about antenatal vaccination; these women were significantly less 
likely to have had, or to intend to have, any antenatal vaccines than those who had received 
information (table 2).  
Forty-six percent (124) stated that the most important source of information would be their 
midwife, with general practitioners and obstetricians being the next most highly-ranked sources 
and the media being least popular. Those who had a discussion with their midwife, general 
practitioner or obstetrician (as opposed to only a leaflet/own research) were more likely to 
have/to intend to have, a vaccine (table 2). Ninety-four percent (258) of maternity professionals 
agreed that information about vaccination in pregnancy was most appropriately delivered by 
midwives.  
Neither age nor having other children appeared to significantly affect the decision to have an 
antenatal vaccination, although White British respondents were significantly more likely to have 
had/to intend to have vaccination than those identifying themselves as Black or White Other, the 
majority of whom were from elsewhere in Europe (table 2).  
Both maternity professionals and pregnant women considered 21-30 weeks’ gestation to be the 
most acceptable time in pregnancy for vaccination (pregnant women: 21.2% (57), maternity 
professionals: 40.7% (111)). Themes emerging from the free text answers for both groups 
included a perception that this was a “safer” time as the baby was more developed and there was 
less risk of miscarriage. 
Knowledge about GBS amongst pregnant women was low with 70% (189) reporting that they 
didn’t know what it was (figure 3). Almost all the maternity professionals (269, 98.5%) and 
neonatal doctors (96, 99%) had some clinical experience of GBS, with similar percentages in 
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both groups reporting they had had discussions with women about GBS (pre or post-natal) or 
prescribed/administered antibiotics for GBS. Most (94.8%, 92) of neonatal doctors had 
experience of caring for a baby with GBS infection compared to 61.5% (168) of maternity 
professionals. Preferred preventive strategies for GBS also varied between the healthcare 
professional groups with universal screening of all pregnant women preferred by maternity 
professionals (116, 42.5%, more than one response permitted) and vaccination by the neonatal 
doctors (48, 49.5%). Only 32.2% (88) and 24.7% (24) respectively felt the current UK risk based 
approach was most appropriate. 
Before and after reading a leaflet with information about GBS, all respondents were asked how 
likely they would be to either have (pregnant women), recommend (maternity professionals) or 
support (neonatal doctors) a GBS vaccine. Prior to reading the information, 42.8% (115) of 
pregnant women stated they would be very/fairly likely to receive the vaccine, which rose to 
68.4% (184) after reading the information (figure 4a). The shift was less dramatic for maternity 
professionals (figure 4b) and there was virtually no change for neonatal doctors (figure 4c).  
Respondents were asked whether they would accept, recommend or support a GBS vaccine 
according to different numbers of previous vaccine recipients in clinical trials (figure 5). The 
percentage of pregnant women willing to accept the vaccine increased from 30% to 60% as the 
hypothetical number of previous recipients increased from 1,000 to 10,000. The most frequently 
cited period of required follow up for adverse outcomes before maternity professionals or 
neonatal doctors would recommend the vaccine was 5 years (133 (48.7%) and 55 (56.7%), 
respectively).  
After reading additional information about the current trial status of GBS vaccines, 23.8% (64) 
of pregnant women stated that they would be very or fairly likely to take part in a clinical trial of 
a GBS vaccine. This was not significantly affected by age, parity, or ethnicity. The most 
frequently preferred mode of recruitment was to be invited by their own midwife (49.8%, 134). 
Internet adverts, for example, on parent forums or emails from the study team were not popular. 
When the concept of a randomised control trial was explained (i.e. that they may or may not 
receive the active vaccine and would not be able to choose), the majority of women (177, 
65.8%) felt this would not affect their decision to take part, however 4.5% (12) would be more 
likely to take part as there was a chance they would not get the vaccine (but still receive the 
benefits of being in the trial) and 12.6% (34) would be less likely to take part as they would want 
a guarantee of receiving the vaccine. 
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Healthcare professionals were generally supportive of GBS vaccine trials with 59.3% (162) of 
maternity professionals and 74.2% (72) of neonatal doctors very or fairly likely to recommend a 
pregnant woman to take part in a trial. Almost all (>99%) wanted to be involved in some 
capacity if their hospital was taking part in a GBS trial, with 78% (213) of maternity 
professionals willing to discuss the trial, 42% (113) to take consent, and 30.5% (82) to 
administer the vaccine. Neonatal doctors were also keen to be involved with 46.4% (45) willing 
to be part of the study team and 41.2% (40) to take consent. 
Among the pregnant women, strong motivators which would make respondents more likely to 
take part in a clinical trial included having extra scans, being tested themselves for GBS 
carriage, their baby having regular check-ups for several years and having extra antenatal 
appointments (Figure 6).  
“I think it's great that a vaccine is being tried and tested to develop into something which can 
save lives and limit effects of GBS.” 
Pregnant woman SP032 
“For me to take part in the trial, I would need time to think about it, real info on the possible 
risks and benefits to myself, my baby and others.  All discussed with my midwife, so it is face to 
face.” 
Pregnant woman OP030 
Concerns expressed in the free text section centred on any risk to the baby, particularly of 
miscarriage,  
“Risk of miscarriage or other health complications for the baby in utero and beyond. I would be 
more likely to take part in research concerning my health alone and not that of an unborn child, 
who has no choice.” 
Pregnant woman SP003 
The potential, unknown, long-term side effects were also a concern and that some women 
disliked the thought of being a “guinea pig”.  
In a similar way, maternity professionals and neonatal doctors were concerned about the 
potential risks to both mother and baby, though the prospect of litigation if things went wrong 
ranked as the third highest concern and extra workload was also a potential issue. 
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Discussion 
This study provides important new insights on the attitudes of pregnant women and healthcare 
professionals towards antenatal vaccination and clinical vaccine trials involving pregnant women 
in the UK. Other attitudinal studies have been conducted mainly in the USA (21), or have 
focused on single vaccines (22) and few have assessed the views of healthcare professionals 
(23), or considered clinical trial participation.   
Our findings suggest that provision of information is key to encourage antenatal vaccine uptake. 
However a significant number of women reported they had not been offered information and 
fears persist about the perceived risk of miscarriage or harm to the baby. Similar concerns have 
been highlighted in other studies exploring attitudes to maternal immunisation, among different 
populations such as in the USA and Australia (21, 22, 24). Our data suggest that emphasising the 
protection for the baby and the potential severity of the infections, rather than benefit for mother 
or protection from a common illness could be more effective at promoting vaccine uptake. This 
may partly explain the difference in uptake between the pertussis and influenza vaccines as 
pertussis is primarily presented as protecting the baby while influenza vaccine programmes are 
primarily designed to protect the pregnant women herself, despite evidence that they can also 
improve the health of babies (3). Differences in the perception of the severity of pertussis and 
influenza for mother and infant have been reported elsewhere, with influenza generally not 
regarded as serious by any group (25).  However other factors, such as the different gestation at 
which these vaccines are recommended, may also play a part.  
It is vital that healthcare professionals are aware of the evidence regarding the safety of antenatal 
vaccination, in particular that there appear to be no increased risks and that there may be 
additional benefits (3, 6, 7, 26), such as improved birthweight. Providing a short, written 
information sheet can be very effective as demonstrated by the 26% increase in pregnant women 
likely to accept a GBS vaccine after reading the information sheet, although for the women 
surveyed here, discussion with a healthcare professional significantly increased the likelihood of 
acceptance compared to written information alone. As well as having knowledge, maternity 
professionals need training about how best to communicate key information to all pregnant 
women. Shortly after the introduction of the antenatal influenza vaccine, Ishola et al found that 
only 26% of London midwives felt well prepared to advise women about the influenza vaccine 
(27). Evidently this is an important area for development. The specific concern about 
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miscarriage, now of particular relevance to both the influenza and pertussis vaccines which may 
be given early in pregnancy, should be actively addressed and reassurance given.  
The low level of awareness among pregnant women about GBS is consistent with other UK 
studies (18) and is perhaps unsurprising in the UK context where screening for GBS is not 
routine (13). However this could have important implications for the uptake of a future GBS 
vaccine and our data suggest that implementation will need to be accompanied by an intensive 
education campaign for both pregnant women and maternity professionals. One other study in 
the USA, exploring the attitudes of pregnant women towards a hypothetical GBS vaccine, 
reported a higher potential acceptance rate of 79% (28) although it is important to note that this 
was in the context of a routine GBS screening programme. 
The data regarding  pregnant women’s’ potential involvement in a clinical trial are novel and are  
of practical relevance for those designing and recruiting to studies of antenatal vaccines 
including not only those against GBS but also other major pathogens such as Respiratory 
Syncytial Virus. Encouragingly, almost a quarter of pregnant women would consider taking part 
in a hypothetical GBS clinical trial and healthcare professionals were also supportive in that they 
would be willing to provide significant practical help to the study teams. The involvement of the 
patient’s own clinician is particularly important in optimising participation (29), although our 
previous qualitative work has suggested that some maternity professionals may be very 
ambivalent about clinical vaccine trials (19). It is reassuring that these were not the views of this 
more representative sample of UK maternity professionals and suggests that recruiting local staff 
to be part of the study team could be key to success. While maternity professionals have the 
most contact with pregnant women, neonatal doctors could also prove to be a valuable resource 
as a group which strongly supports antenatal vaccination and could be involved in long-term 
postnatal follow up, an important motivator for the pregnant women. Contrary to the usual 
emphasis on minimising the number of visits to cause as little inconvenience as possible in many 
standard vaccine studies, it seems that offering additional time, scans and appointments could 
improve the likelihood of pregnant women participating, while incentives such as vouchers or 
money would have little effect on recruitment. A previous study of mostly non-pregnant women 
had indicated that those with children might be more likely to take part in a clinical vaccine trial 
(30), although the differences here were not significant. In the same study among non-pregnant 
women, 32% of respondents indicated they would be very/fairly likely to take part (18) 
compared to 23.8% of the pregnant women surveyed here. However, for women who are 
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pregnant, the scenario of engaging in a vaccine study while pregnant is closer to their current 
situation and the results shown here are more likely to reflect reality. 
There are a number of limitations to this study to be acknowledged. Only respondents who could 
read and write English were included, thus we excluded important groups who are likely to have 
particular challenges in accessing information and the vaccines themselves. Future work should 
make special efforts to reach this under-represented population. While the ethnic background of 
our sample was proportionally representative of the UK population, there were relatively few 
respondents from ethnic minorities and ethnicity is known to influence attitudes towards 
healthcare and vaccination (21, 22). Similarly, there should be caution in extrapolating these data 
to populations where screening for GBS is routine in whom background knowledge of GBS 
among pregnant women may be greater. Though a high proportion of those approached (75-
85%) agreed to take part in the study, no data were collected on those who declined to 
participate and although a broad range of ages, gestations and parity were included, we cannot 
rule out responder bias. Only vaccine trials and real life implementation will confirm whether 
the interventions suggested by these data are able increase vaccine uptake. 
 
Antenatal vaccination is an important tool with increasing potential to reduce both maternal and 
neonatal mortality and morbidity, if it can be delivered effectively. In keeping with previous 
studies, these data show that both pregnant women and the healthcare professionals do have 
concerns about the use of vaccination in pregnancy, but encouragingly many are open to the 
concept of novel vaccines and willing to participate in research to bring these forward. 
Education of both pregnant women and those caring for them is key to both improve uptake of 
current and future vaccines and help optimise recruitment for clinical trials to further reduce the 
burden of neonatal disease both in the UK and worldwide.  
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Supporting Information legends 
Appendix S1: Survey questions for pregnant women, maternity professionals and neonatal 
doctors. 
Appendix S2: GBS fact sheet. 
 
Table and figure legends 
 
Table 1 Participant demographic details (percentages rounded to one decimal place). 
 
Table 2 Had/intend to have antenatal vaccination according to whether information received and 
ethnicity. 
 
Figure 1: Pregnant women, perceived benefits of antenatal vaccination. 1 = most important, 7 = 
least important (n= number of respondents giving that rank to any statement). 
 
Figure 2: Pregnant women, concerns about antenatal vaccines. 1= greatest concern, 10 = least 
(n= number of respondents giving that rank to any statement). 
 
Figure 3: Pregnant women, “Have you heard of group B streptococcus (sometimes called Group 
B strep or GBS)?” Of the 22 (8%) women who reported being directly affected by GBS, 2 
indicated having a previous child with GBS infection, 11 a positive GBS swab in this or a 
previous pregnancy, 6 knew a friend/family who had a child with GBS infection, 1 reported that 
she had had GBS, 1 that a friend had been told her recurrent miscarriages could be due to GBS 
and another did not specify. 
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Figure 4: a) Pregnant women, b) maternity professionals and c) neonatal doctors, likelihood of 
receiving/recommending/supporting an antenatal vaccination against GBS before and after 
reading information sheet. 
 
Figure 5: Number of pregnant women who would have to have had the vaccine before each 
group would consider receiving, recommending or supporting a GBS vaccine. 
 
Figure 6: Pregnant women, motivators to take part in a GBS vaccine trial. 1 = most preferred, 9 
= least preferred. (n= number of respondents giving that rank to any statement). 20% (54) stated 
that nothing would make them more likely to take part. 
 
